Imara
demonstrated robust anti tumor activity in her intracranial model at well tolerated doses | Imara
Company
Deck Type
Deck date
October 2022
Slide
41 of 45
Similar slides by Imara
See diffirences between slides (animation)
Mergers and Acquisitions
October 2022
demonstrated robust anti tumor activity in her model at well tolerated doses | Imara
Related slides by other companies
Immatics
Investor Presentation
November 2023
assessment of anti tumor activity in | Immatics
BioNTech
Results
November 2020
phase a anti tumor activity dose disease control achieved in of patients four patients with | BioNTech
BioNTech
Results
November 2020
phase a anti tumor activity in immune recurrent refractory expansion | BioNTech
Nuvalent
Investor Presentation
January 2024
potential best in class profile for opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc mutation disease current soc of disease demonstrated activity where current available therapies have failed opportunity to supplant standard of care with a differentiated clinical activity observed in heavily patients with who likely exhausted all available therapies including after or with resistance mutations with history of metastasis including intracranial responses to address combined medical needs mutation coverage activity avoiding off target adverse events opportunity to drive deep durable responses favorable preliminary safety consistent with selective sparing design sources sales and forecasts accessed lin precision and lung cancer a | Nuvalent
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io